Drugs in Dev. Endocrinology
Preclinical
India 
Lead Product(s) : MKP10241
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mankind Pharma Gets CDSCO Panel Nod for Phase I Trial of Anti-Diabetic Drug, MKP10241
Details : MKP10241, a new class of anti-diabetic molecules, is designed and developed at the Mankind Research Centre. It is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is highly expressed in pancreatic beta cells and intestinal enteroe...
Product Name : MKP10241
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2021
Lead Product(s) : MKP10241
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Utreglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sun Pharma Announces Pre-Clinical Data on GL0034 to Treat Type 2 Diabetes and Obesity
Details : Pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters and a marked and meaningful reduction in triglyceride levels.
Product Name : GL0034
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : Utreglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
